CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
MetadataShow full item record
Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast cancers as well as glioblastoma, melanoma, non-small cell lung cancer, colorectal cancer, and ovarian cancer. The development of abemaciclib and other CDK4/6 inhibitors should now be fully optimized through the use of novel predictive biomarkers of response and rational combinations. Cancer Discov; 6(7); 697-9. ©2016 AACRSee related article by Patnaik et al., p. 740.
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Clinical Trials as Topic
Medicine Drug Development Unit (de Bono)
License start date
Cancer discovery, 2016, 6 (7), pp. 697 - 699